Patents

Literature

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

105 results about "CETP inhibitor" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

A CETP inhibitor is a member of a class of drugs that inhibit cholesterylester transfer protein (CETP). They are intended to reduce the risk of atherosclerosis (a cardiovascular disease) by improving blood lipid levels. At least three medications within this class have failed to result in benefits however.

Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline

InactiveUS6313142B1Improve isolationEasy to purifyBiocideMetabolism disorderStereochemistryCETP inhibitor

Methods of preparing CETP inhibitors are disclosed.

Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline

Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline

Owner:PFIZER INC

CETP inhibitors

ActiveUS20060040999A1BiocideGroup 4/14 element organic compoundsArylPhenyl group

Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH2—.

CETP inhibitors

CETP inhibitors

CETP inhibitors

Owner:MERCK SHARP & DOHME LLC

Cholesteryl Ester Transfer Protein Inhibitors

ActiveUS20090018054A1BiocideOrganic chemistryCombinatorial chemistryCholesteryl ester

Compounds of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), A1 is a cyclic group, and B is a cyclic group which is attached to the heterocyclic ring directly or through a methylene group.

Cholesteryl Ester Transfer Protein Inhibitors

Cholesteryl Ester Transfer Protein Inhibitors

Cholesteryl Ester Transfer Protein Inhibitors

Owner:MERCK SHARP & DOHME LLC

1,2,3,4-tetrahydro-quinoline derivatives as CETP inhibitors

InactiveUS20070265304A1BiocideOrganic chemistryQuinolineCETP inhibitor

The invention is directed to compounds of Formula (I) described herein useful as CETP inhibitors, compositions containing them, and methods of using them.

1,2,3,4-tetrahydro-quinoline derivatives as CETP inhibitors

1,2,3,4-tetrahydro-quinoline derivatives as CETP inhibitors

1,2,3,4-tetrahydro-quinoline derivatives as CETP inhibitors

Owner:JANSSEN PHARMA NV

Method of reducing C-reactive protein using growth hormone secretagogues

InactiveUS20050261201A1Good treatment effectBiocideNervous disorderHMG-CoA reductaseBeta blocker

The present invention relates to a method of reducing C-reactive protein in a subject in need of treatment thereof, wherein the subject is at risk of having or the subject has already had a vascular event or suffering from an inflammatory disease or disorder. In one embodiment, the vascular event is a cardiovascular event (e.g., myocardial infarction). In another embodiment, the vascular event is a cerebrovascular event (e.g., stroke (such as transient ischemic attacks (TIAs)). In yet another embodiment the vascular event is a peripheral vascular event (e.g., intermittent claudication). The method comprises administering a therapeutically effective amount of at least one growth hormone secretagogue compound or a pharmaceutically acceptable salt, hydrate or solvate thereof. The growth hormone secretagogue can be coadministered with a second growth hormone secretagogue, HMG CoA reductase inhibitor, an ACAT inhibitor, a CETP inhibitor, an anti-inflammatory agent, an ACE inhibitor, a Beta blocker, a cholesterol absorption inhibitor, a nicotonic acid, a fibric acid derivative, a bile acid sequestering agent or a combination thereof.

Method of reducing C-reactive protein using growth hormone secretagogues

Method of reducing C-reactive protein using growth hormone secretagogues

Method of reducing C-reactive protein using growth hormone secretagogues

Owner:HELSINN THERAPEUTICS (US) INC

3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as CETP inhibitors

InactiveUS20070265252A1Organic chemistryMetabolism disorderThiazineCETP inhibitor

The invention is directed to compounds of Formula (I) described herein useful as CETP inhibitors, compositions containing them, and methods of using them.

3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as CETP inhibitors

3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as CETP inhibitors

3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as CETP inhibitors

Owner:JANSSEN PHARMA NV

Novel benzylamine derivatives as CETP inhibitors

InactiveUS20060178514A1Organic chemistryMetabolism disorderLipoxinBenzylamine

The present invention provides, among other things, new benzylamine compounds, compositions comprising benzylamine compounds, methods of making benzylamine compounds, and methods of using benzylamine compounds for treating or preventing a variety of conditions or diseases associated with lipoprotein metabolism.

Novel benzylamine derivatives as CETP inhibitors

Novel benzylamine derivatives as CETP inhibitors

Novel benzylamine derivatives as CETP inhibitors

Owner:DR REDDYS LAB LTD

Polymer Formulations of CETP Inhibitors

ActiveUS20100227903A1Improve bioavailabilityGood dispersionHalogenated hydrocarbon active ingredientsBiocideChemical compoundSURFACTANT BLEND

A pharmaceutical composition comprises (a) a CETP inhibiting compound, or a pharmaceutically acceptable salt thereof; (b) a concentration-enhancing polymer, and (c) optionally one or more surfactants; wherein the compound has the structure shown as Formula I below. The composition raises HDL-cholesterol and lowers LDL-cholesterol.

Polymer Formulations of CETP Inhibitors

Polymer Formulations of CETP Inhibitors

Polymer Formulations of CETP Inhibitors

Owner:MERCK SHARP & DOHME LLC

Pentacyclic triterpenoid cholesterol ester transfer protein (CETP) inhibitor, pharmaceutical composition thereof and medical application

InactiveCN104725456AOrganic active ingredientsNervous disorderDiseaseTriterpene

The invention relates to the pharmaceutical field, in particular to application of a series of pentacyclic triterpenoid compounds as a cholesterol ester transfer protein (CETP) inhibitor, in particular to application in factors of preparing medicines for treating cardiovascular and cerebrovascular diseases, atherosclerosis diseases and hyperlipemia. The invention further discloses a series of novel pentacyclic triterpenoid compounds, application of the compounds as the CETP inhibitor and a pharmaceutical composition.

Pentacyclic triterpenoid cholesterol ester transfer protein (CETP) inhibitor, pharmaceutical composition thereof and medical application

Pentacyclic triterpenoid cholesterol ester transfer protein (CETP) inhibitor, pharmaceutical composition thereof and medical application

Pentacyclic triterpenoid cholesterol ester transfer protein (CETP) inhibitor, pharmaceutical composition thereof and medical application

Owner:CHINA PHARM UNIV

Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors

InactiveUS20040132771A1Overcomes drawbackImprove concentrationPowder deliveryBiocideHMG-CoA reductaseBioavailability

A composition comprises (1) a solid amorphous adsorbate comprising a cholesteryl ester transfer protein (CETP) inhibitor and a substrate; and (2) an HMG-CoA reductase inhibitor. The solid amorphous adsorbate provides concentration enhancement of the CETP inhibitor relative to a control composition consisting essentially of the unadsorbed CETP inhibitor alone, resulting in improved bioavailability.

Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors

Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors

Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors

Owner:BEND RES

1,3-Oxazolidin-2-One Derivatives Useful as Cetp Inhibitors

ActiveUS20090137548A1BiocideOrganic chemistryOxazolidine EMedicine

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. The compounds have 3 cyclic groups connected by single bonds, as for example triphenyl, which are attached directly to the ring of formula I or attached at the position B.

1,3-Oxazolidin-2-One Derivatives Useful as Cetp Inhibitors

1,3-Oxazolidin-2-One Derivatives Useful as Cetp Inhibitors

1,3-Oxazolidin-2-One Derivatives Useful as Cetp Inhibitors

Owner:MERCK SHARP & DOHME LLC

Cetp Inhibitors

ActiveUS20090042892A1BiocideOrganic chemistryCETP inhibitorLdl cholesterol

Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), B is a cyclic group other than phenyl, and B has a cyclic substituent at a position that is ortho to the position at which B is connected to the remainder of the structure of Formula (I). The 5-membered ring of Formula (I) has a second cyclic substituent in addition to B.

Cetp Inhibitors

Cetp Inhibitors

Cetp Inhibitors

Owner:MERCK SHARP & DOHME LLC

CETP inhibitors

ActiveUS7781426B2BiocideOrganic chemistryPharmaceutical medicinePhenyl group

Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), B or R2 is a phenyl group which has an ortho amine or aminomethyl substituent which is further substituted, and the other of B or R2 is also a cyclic group.

CETP inhibitors

CETP inhibitors

CETP inhibitors

Owner:MERCK SHARP & DOHME LLC

CETP inhibitors

ActiveUS7737295B2BiocideCarbamic acid derivatives preparationDecreasing ldlStereochemistry

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, A1 and A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring.

CETP inhibitors

CETP inhibitors

CETP inhibitors

Owner:MERCK SHARP & DOHME LLC

CETP inhibitors derived from benzoxazole arylamides

ActiveUS8445480B2Increasing HDL-cholesterolLowering LDL-cholesterolBiocideOrganic chemistryVascular diseaseBenzoxazole

Compounds having the structure of Formula I1 including pharmaceutically acceptable salts of the compounds, are potent CETP (cholesterol ester transfer protein) inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis Atherosclerosis and its clinical consequences, coronary heart disease (CHD), stroke and penpheral vascular disease, represent a truly enormous burden to the health care systems of the industrialized world In formula I, A-B is an arylamide moiety.

CETP inhibitors derived from benzoxazole arylamides

CETP inhibitors derived from benzoxazole arylamides

CETP inhibitors derived from benzoxazole arylamides

Owner:MERCK SHARP & DOHME LLC

CETP inhibitors derived from benzoxazole arylamides

ActiveUS8436028B2Increasing HDL-cholesterolLowering LDL-cholesterolBiocideSilicon organic compoundsBenzoxazoleDecreasing ldl

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are potent CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In formula I, A-B is an arylamide moiety.

CETP inhibitors derived from benzoxazole arylamides

CETP inhibitors derived from benzoxazole arylamides

CETP inhibitors derived from benzoxazole arylamides

Owner:MERCK SHARP & DOHME LLC

CETP inhibitors

ActiveUS7910592B2BiocideOrganic chemistryOrtho positionCETP inhibitor

Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), B is a cyclic group other than phenyl, and B has a cyclic substituent at a position that is ortho to the position at which B is connected to the remainder of the structure of Formula (I). The 5-membered ring of Formula (I) has a second cyclic substituent in addition to B.

CETP inhibitors

CETP inhibitors

CETP inhibitors

Owner:MERCK SHARP & DOHME LLC

1,3-oxazolidin-2-one derivatives useful as CETP inhibitors

ActiveUS7915271B2BiocideOrganic chemistryPharmaceutical medicinePerylene derivatives

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. The compounds have 3 cyclic groups connected by single bonds, as for example triphenyl, which are attached directly to the ring of formula I or attached at the position B.

1,3-oxazolidin-2-one derivatives useful as CETP inhibitors

1,3-oxazolidin-2-one derivatives useful as CETP inhibitors

1,3-oxazolidin-2-one derivatives useful as CETP inhibitors

Owner:MERCK SHARP & DOHME LLC

Polymer formulations of CETP inhibitors

InactiveUS8030359B2Improve bioavailabilityGood dispersionHalogenated hydrocarbon active ingredientsBiocideCompound (substance)SURFACTANT BLEND

A pharmaceutical composition comprises (a) a CETP inhibiting compound, or a pharmaceutically acceptable salt thereof; (b) a concentration-enhancing polymer, and (c) optionally one or more surfactants; wherein the compound has the structure shown as Formula I below. The composition raises HDL-cholesterol and lowers LDL-cholesterol.

Polymer formulations of CETP inhibitors

Polymer formulations of CETP inhibitors

Polymer formulations of CETP inhibitors

Owner:MERCK SHARP & DOHME LLC

Bicyclic ureas and thiadiazolidine-1, 1-dioxides as CETP inhibitors

ActiveUS9981970B2Organic active ingredientsOrganic chemistryDecreasing ldlStereochemistry

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, wherein X is —C(═O) or —S(O)2—, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.

Bicyclic ureas and thiadiazolidine-1, 1-dioxides as CETP inhibitors

Bicyclic ureas and thiadiazolidine-1, 1-dioxides as CETP inhibitors

Bicyclic ureas and thiadiazolidine-1, 1-dioxides as CETP inhibitors

Owner:MERCK SHARP & DOHME LLC

CETP Inhibitors

ActiveUS20090075979A1BiocideOrganic chemistryMethyl groupPhenyl group

Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), B or R2 is a phenyl group which has an ortho amine or aminomethyl substituent which is further substituted, and the other of B or R2 is also a cyclic group.

CETP Inhibitors

CETP Inhibitors

CETP Inhibitors

Owner:MERCK SHARP & DOHME LLC

Use of CETP inhibitors and optionally HMG COA reductable inhibitors and/or antihypertensive agents

InactiveCN1665537ASenses disorderNervous disorderDiseaseDepressant

The present invention relates to cholesteryl ester transfer protein (CETP) inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors optionally in combination with certain therapeutic agents, such as antihypertensive agents, in the treatment of certain diseases / disorders Applications.

Use of CETP inhibitors and optionally HMG COA reductable inhibitors and/or antihypertensive agents

Use of CETP inhibitors and optionally HMG COA reductable inhibitors and/or antihypertensive agents

Use of CETP inhibitors and optionally HMG COA reductable inhibitors and/or antihypertensive agents

Owner:PFIZER PRODS ETAT DE CONNECTICUT

Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors

InactiveUS20060014788A1Reduce food effectGood miscibilityBiocideOrganic chemistrySolventCholesteryl ester

CETP Inhibitors have improved solubility and bioavailability in a lipophilic vehicle comprising a digestible oil, a lipophilic solvent, or a surfactant. Preferred such compositions are self-emulsifying or self-microemulsifying, and comprise 1. a CETP inhibitor; 2. a cosolvent; 3. a surfactant having an HLB of 1 to 8; 4. a surfactant having an HLB of over 8 to 20; and 5. optionally, a digestible oil.

Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors

Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors

Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors

Owner:PFIZER INC

Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent

ActiveUS20170233812A1Organic active ingredientsMetabolism disorderHdl raisingCETP inhibitor

Genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor / modulator

Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent

Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent

Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent

Owner:F HOFFMANN LA ROCHE & CO AG

CETP inhibitors

ActiveUS8334290B2BiocideOrganic chemistryCombinatorial chemistryCETP inhibitor

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.

CETP inhibitors

CETP inhibitors

CETP inhibitors

Owner:MERCK SHARP & DOHME LLC

Heterocyclic CETP inhibitors

ActiveUS7790770B2BiocideGroup 4/14 element organic compoundsCETP inhibitorChemistry

Compounds of formula Ia and Ibwherein A, B, C and R1 are described herein.

Heterocyclic CETP inhibitors

Heterocyclic CETP inhibitors

Heterocyclic CETP inhibitors

Owner:BRISTOL MYERS SQUIBB CO

Fused bicyclic oxazolidinone CETP inhibitor

ActiveUS8871738B2BiocideOrganic chemistryPharmaceutical medicinePharmacology

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.

Fused bicyclic oxazolidinone CETP inhibitor

Fused bicyclic oxazolidinone CETP inhibitor

Fused bicyclic oxazolidinone CETP inhibitor

Owner:MERCK SHARP & DOHME LLC

Cetp Inhibitors

InactiveUS20080119476A1BiocideGroup 4/14 element organic compoundsArylPhenyl group

Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis:In the compounds of Formula I, B or R2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH2—.

Cetp Inhibitors

Cetp Inhibitors

Cetp Inhibitors

Owner:ALI AMJAD +12

Prodrugs of oxazolidinone CETP inhibitors

ActiveUS20110218177A1Easy to convertBiocideOrganic compound preparationStereochemistryCETP inhibitor

The compounds of Formula I are pro-drugs of CETP inhibitors having a central oxazolidinone ring. The compounds cyclize by the elimination of HX to form an oxazolidinone ring after administration to a patient.

Prodrugs of oxazolidinone CETP inhibitors

Prodrugs of oxazolidinone CETP inhibitors

Prodrugs of oxazolidinone CETP inhibitors

Owner:MERCK SHARP & DOHME LLC

1,2,3,4-tetrahydro-quinoline derivatives as CETP inhibitors

InactiveUS7928238B2BiocideOrganic chemistryQuinolineCETP inhibitor

The invention is directed to compounds of Formula (I) described herein useful as CETP inhibitors, compositions containing them, and methods of using them.

1,2,3,4-tetrahydro-quinoline derivatives as CETP inhibitors

1,2,3,4-tetrahydro-quinoline derivatives as CETP inhibitors

1,2,3,4-tetrahydro-quinoline derivatives as CETP inhibitors

Owner:JANSSEN PHARMA NV

Popular searches

Photochemistry Substituent HDL cholesterol ester Atherosclerosis prevention Cholesterol absorption inhibitor Risk stroke Intermittent claudication Disease cause Disease injury Growth hormone secretagogue

Who we serve

R&D Engineer
R&D Manager
IP Professional

Why Patsnap Eureka

Industry Leading Data Capabilities
Powerful AI technology
Patent DNA Extraction

Social media

Patsnap Eureka Blog

PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com